Time Course for Omalizumab Examined in Early, Late Allergic Reaction

This article originally appeared here.
Significant reduction in early allergic reaction after 4 weeks, with decrease in FEV1, exhaled nitric oxide
Significant reduction in early allergic reaction after 4 weeks, with decrease in FEV1, exhaled nitric oxide

HealthDay News — For patients with a significant response to allergen challenge, omalizumab induces protective effects against early (EAR) and late allergic reactions (LAR), according to a study published online June 5 in Allergy.

Jordis Trischler, MD, from the University Hospital Frankfurt in Germany, and colleagues determined the time course of the early (EAR) and late allergic reaction (LAR). Ten patients with a significant response to allergen challenge were treated with omalizumab. At week 1, 2, 4, and 4, bronchial allergen provocations were repeated.

The researchers observed a significant reduction in EAR after 4 weeks (change in forced expiratory volume in 1 second [ΔFEV1], 28 versus 11%; P<0.001; exhaled nitric oxide, 86 versus 53 ppb; P<0.05), and there was a reduction in basophil activation after two weeks (CD63 expression, 79 versus 32%; P<0.05). After one week there was a reduction in LAR (ΔFEV1, 26 versus 13%; P<0.05). 

Related Articles

"These results demonstrate the onset of protective effects earlier than previously determined, potentially improving seasonal utilization and combination with immunotherapy," the authors write.

Abstract
Full Text (subscription or payment may be required)